Literature DB >> 26233437

Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.

Masako Mizusawa1, Shira Doron, Sherwood Gorbach.   

Abstract

Clostridium difficile infection (CDI) is the most common cause of infectious diarrhea in healthcare settings. Along with antimicrobial exposure, advanced age has been shown to be a significant risk factor for the development and recurrence of, and mortality from, CDI. The substantial burden of CDI in the elderly may be related to frequent healthcare exposure, the necessity for more medications, altered intestinal microbiota, and complicated comorbidities. A diagnosis of CDI is based on evidence of toxin, or the C. difficile organism itself, in a stool sample in the presence of clinical signs and symptoms. Only symptomatic patients should be tested for CDI, and routine surveillance or repeat testing on asymptomatic patients as a test of cure is discouraged. Antibiotic discontinuation alone can improve or resolve CDI in some patients, and concomitant use of antibiotics is associated with decreased response to CDI treatment. Metronidazole, vancomycin, and fidaxomicin are the therapeutic agents currently available for CDI, with the selection of these agents being based on disease severity, history of recurrence, and cost. The recurrence rate after initial treatment is 20-30%. The first recurrence can be treated with the same therapeutic agent and, for subsequent recurrences, vancomycin in a tapered and/or pulsed regimen is recommended. Fecal microbiota transplantation has shown remarkable effectiveness for recurrent anti-refractory CDI, although caution is advised in treating immunocompromised hosts and those with toxic megacolon. C. difficile can be transmitted directly and indirectly via contact with patients or their environment; therefore, isolation precautions should be initiated at the first suspicion of CDI. C. difficile spores can survive for a long time on environmental surfaces, and the patient's room and all equipment used in the room should be disinfected. In order to manage CDI in the elderly, timely diagnosis, appropriate treatment based on severity of illness, and effective infection control are essential.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26233437     DOI: 10.1007/s40266-015-0289-2

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  79 in total

1.  C. difficile: by the numbers.

Authors:  Laura Eggertson
Journal:  CMAJ       Date:  2004-11-02       Impact factor: 8.262

2.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

3.  Saccharomyces boulardii fungemia caused by treatment with a probioticum.

Authors:  Julie Bjerre Thygesen; Henning Glerup; Britta Tarp
Journal:  BMJ Case Rep       Date:  2012-03-27

4.  Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness.

Authors:  Jong Hun Kim; Diana Toy; Robert R Muder
Journal:  Infect Control Hosp Epidemiol       Date:  2011-07       Impact factor: 3.254

5.  Extended spectrum cephalosporins and Clostridium difficile.

Authors:  C L Golledge; T McKenzie; T V Riley
Journal:  J Antimicrob Chemother       Date:  1989-06       Impact factor: 5.790

6.  Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

Authors:  Wafa N Al-Nassir; Ajay K Sethi; Michelle M Nerandzic; Greg S Bobulsky; Robin L P Jump; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2008-07-01       Impact factor: 9.079

7.  Clostridium difficile colitis.

Authors:  J M Rocca; A S Pieterse; R Rowland; R Hecker; G E Rich
Journal:  Aust N Z J Med       Date:  1984-10

8.  Case report. Clindamycin associated pseudomembranous colitis.

Authors:  J Beesley; E J Eastham; R H Jackson; R Nelson
Journal:  Acta Paediatr Scand       Date:  1981-01

9.  Clostridium difficile infection in Ohio hospitals and nursing homes during 2006.

Authors:  Robert J Campbell; Lynn Giljahn; Kim Machesky; Katie Cibulskas-White; Lisa M Lane; Kyle Porter; John O Paulson; Forrest W Smith; L Clifford McDonald
Journal:  Infect Control Hosp Epidemiol       Date:  2009-06       Impact factor: 3.254

10.  Reduction of Clostridium Difficile and vancomycin-resistant Enterococcus contamination of environmental surfaces after an intervention to improve cleaning methods.

Authors:  Brittany C Eckstein; Daniel A Adams; Elizabeth C Eckstein; Agam Rao; Ajay K Sethi; Gopala K Yadavalli; Curtis J Donskey
Journal:  BMC Infect Dis       Date:  2007-06-21       Impact factor: 3.090

View more
  8 in total

Review 1.  Nutrition and the gut microbiome in the elderly.

Authors:  Nuria Salazar; Lorena Valdés-Varela; Sonia González; Miguel Gueimonde; Clara G de Los Reyes-Gavilán
Journal:  Gut Microbes       Date:  2016-11-03

Review 2.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 3.  The Gut Microbiome as a Therapeutic Target for Cognitive Impairment.

Authors:  Yi Sun; Liliana C Baptista; Lisa M Roberts; Patricia Jumbo-Lucioni; Lori L McMahon; Thomas W Buford; Christy S Carter
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-06-18       Impact factor: 6.053

4.  Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series.

Authors:  Benjamin Davido; Céline Leplay; Frédérique Bouchand; Aurélien Dinh; Maryvonne Villart; Jean-Laurent Le Quintrec; Laurent Teillet; Jérôme Salomon; Hugues Michelon
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

5.  Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.

Authors:  Miguel Salavert; Javier Cobo; Álvaro Pascual; Belén Aragón; Stefano Maratia; Yiling Jiang; Susana Aceituno; Santiago Grau
Journal:  Adv Ther       Date:  2018-10-16       Impact factor: 3.845

6.  Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.

Authors:  Thorsten Fuereder; Danjel Koni; Andreas Gleiss; Michael Kundi; Athanasios Makristathis; Christoph Zielinski; Christoph Steininger
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

7.  A Novel Method to Mask the Bitter Taste of Berberine Hydrochloride: Powder Surface Modification.

Authors:  Hong Jiang; Dingkun Zhang; Jing He; Xue Han; Junzhi Lin; Yang Lan; Xi Xiong; Lingying Yu; Ming Yang; Li Han
Journal:  Pharmacogn Mag       Date:  2018-04-10       Impact factor: 1.085

8.  Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016.

Authors:  Kotaro Aoki; Shinobu Takeda; Takashi Miki; Yoshikazu Ishii; Kazuhiro Tateda
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.